C4X Discovery Holdings plc

C4XD

GB00BQQ2RV18

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 05:48:50 2024-04-16 am EDT			5-day change	1st Jan Change
9.44 ^GBX	+10.73%		-0.63%	+4.89%

Apr. 15	C4X Discovery shareholders approve of taking firm private	AN
Mar. 27	C4X Discovery seeks AIM delisting but half-year revenue skyrockets	AN

UK shareholder meetings calendar - next 7 days

January 17, 2023 at 10:56 am EST

Wednesday 18 January
Diploma PLC	AGM
GCM Resources PLC	AGM
John Lewis of Hungerford PLC	AGM
Tlou Energy Ltd	GM re share placing
Topps Tiles PLC	AGM
Tracsis PLC	AGM
WH Smith PLC	AGM
Thursday 19 January
Cardiff Property PLC	AGM
Equipmake Holdings PLC	AGM
J Smart & Co (Contractors) PLC	AGM
Pioneer Media Holdings Inc	AGM
Scotgold Resources Ltd	AGM
Friday 20 January
Appreciate Group PLC	GM re acquisition by PayPal Holdings Inc and Court Meeting
Character Group PLC	AGM
Monday 23 January
Midatech Pharma PLC	GM re proposed acquisition of Bioasis Technologies Inc
Tuesday 24 January
C4X Discovery Holdings PLC	AGM
Smiths News PLC	AGM

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
DIPLOMA PLC	3,485 GBX	-2.65%	-3.06%	5.98B
WH SMITH PLC	1,252 GBX	-0.87%	-4.95%	2.04B
TRACSIS PLC	842.8 GBX	-0.85%	-2.57%	320M
TESCO PLC	281.6 GBX	-1.62%	-2.10%	24.86B
THE CHARACTER GROUP PLC	275.9 GBX	-0.40%	+1.06%	65.35M
PAYPAL HOLDINGS, INC.	63.51 USD	-1.67%	-4.27%	66.85B
SMITHS NEWS PLC	48.85 GBX	+0.21%	+1.03%	144M
TOPPS TILES PLC	41.5 GBX	0.00%	-0.24%	102M
C4X DISCOVERY HOLDINGS PLC	9.44 GBX	+10.73%	-0.63%	26.79M
GCM RESOURCES PLC	7.98 GBX	-7.48%	-7.21%	26.39M

Latest news about C4X Discovery Holdings plc

C4X Discovery shareholders approve of taking firm private	Apr. 15	AN
C4X Discovery seeks AIM delisting but half-year revenue skyrockets	Mar. 27	AN
C4X Discovery Seeks to Delist From London's AIM Amid Financial Markets Downturn	Mar. 27	MT
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Posts Fiscal H1 Revenue GBP24.6M	Mar. 27	MT
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Reports Fiscal H1 EPS GBX7.06	Mar. 27	MT
C4X Discovery Holdings plc Reports Earnings Results for the Half Year Ended January 31, 2024	Mar. 27	CI
C4X Discovery Holdings plc Announces Stepping Down of Mario Polywka as Non-Executive Director	Jan. 18	CI
Stocks down ahead of US Fed minutes	Jan. 03	AN
Stocks down before Fed minutes and US PMI data	Jan. 03	AN
AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals	Jan. 03	AN
Stocks mixed pre-Fed minutes, amid Asia losses	Jan. 03	AN
C4X receives USD11 million from AstraZeneca following NRF2 trials	Jan. 03	AN
Stocks to open flat pre-Fed minutes, jobs data	Jan. 03	AN
C4X Discovery Shares Rise on AstraZeneca Milestone Payment	Jan. 03	DJ
C4X Discovery Receives $11 Million Milestone Payment from AstraZeneca	Jan. 03	MT
C4X Discovery Holdings plc Receives Milestone Payment of $11 Million from AstraZeneca	Jan. 03	CI
C4X Discovery shares topple 10% as loss widens on higher costs	Dec. 14	AN
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Posts FY23 Revenue GBP1.7M	Dec. 14	MT
Earnings Flash (C4XD.L) C4X DISCOVERY HOLDINGS Reports FY23 Loss GBX-4.42	Dec. 14	MT
C4X Discovery Holdings plc Reports Earnings Results for the Full Year Ended July 31, 2023	Dec. 14	CI
Transcript : C4X Discovery Holdings plc, 2023 Earnings Call, Dec 14, 2023	Dec. 14
C4X Discovery inks Indivior deal, Digitalbox expands	23-08-01	AN
FTSE 100 Index Down 0.4% at Close, Dragged by Miners, Oil Stocks	23-08-01	DJ
C4X Discovery to Sell Substance Use Disorder Program to Indivior for GBP16 Million	23-08-01	MT
FTSE 100 Closes Down 0.2% Dragged by Oil, Mining Stocks	23-06-20	DJ

Chart C4X Discovery Holdings plc

Duration

Period

More charts

C4X Discovery Holdings plc is a drug discovery company. The Company has a portfolio ranging from early-stage target opportunities to late-stage drug discovery programs. The Company has three commercially partnered programs with one candidate in clinical development. Its portfolio focuses on treatments for immuno-inflammatory diseases. The Companyâs pipeline products include MALT-1 Inhibitor, a4B7 Integrin Inhibitor, IL-17A Inhibitor, NRF-2 Activator, and others. Its target identification platform (Taxonomy3) is used to analyze complex genetic datasets to identify and characterize drug target candidates. Taxonomy3 offers the potential for patient stratification in clinical trials, ensuring patient targeting and the potential for rescuing failed clinical trials or for drug repurposing. PatientSeek is its new platform that applies the mathematical approach of Taxonomy3 to stratify patients for treatments based on their genetics.

Sector

Biotechnology & Medical Research

Calendar

2024-12-11 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for C4X Discovery Holdings plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0852 GBP

Average target price

0.5 GBP

Spread / Average Target

+486.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
C4X DISCOVERY HOLDINGS PLC	+4.89%	26.79M
IQVIA HOLDINGS INC.	-0.10%	42.07B
LONZA GROUP AG	+48.04%	42.16B
MODERNA, INC.	+4.43%	39.77B
CELLTRION, INC.	-11.36%	26.68B
ICON PUBLIC LIMITED COMPANY	+5.67%	24.68B
ALNYLAM PHARMACEUTICALS, INC.	-22.84%	18.68B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.20%	12.11B
MEDPACE HOLDINGS, INC.	+26.30%	11.99B
UNITED THERAPEUTICS CORPORATION	+6.91%	11.06B